HC Wainwright Reiterates Buy Rating on Relmada Therapeutics
HC Wainwright maintains its buy stance on Relmada Therapeutics with a $12 price target.
Key Points
- On June 18, 2026, HC Wainwright reiterated its buy rating on Relmada Therapeutics, Inc. (RLMD) with a price target of $12.
- Shares of RLMD traded at $6.60, with a market cap of about $705.9 million and a 52-week range of $0.52 to $8.00.
- Recent insider buying at Relmada included the CEO and CFO purchasing shares at $4.12 each in December 2025.
On June 18, 2026, HC Wainwright reiterated its buy rating on Relmada Therapeutics, Inc. (NasdaqCM: RLMD), setting a price target of $12. The move comes as the stock trades around $6.60.
Other Institutional Activity in Relmada Therapeutics
Several institutional investors have made notable changes to their positions in Relmada. Janus Henderson Group PLC increased its holdings by 3,793,862 shares, ending with 11,063,862 shares valued at approximately $76.9 million. Squadron Capital Management LLC also added 1,774,571 shares, bringing its total to 8,474,571 shares worth about $58.9 million. Spruce Street Capital LP boosted its stake by 2,175,933 shares, resulting in 6,262,114 shares valued at nearly $43 million. Venrock Adviser, LLC initiated a position with 4,843,380 shares, valued at roughly $33.7 million. OrbiMed Advisors LLC increased its holdings by 2,105,264 shares, ending with 4,715,864 shares worth about $32.8 million.
Relmada Therapeutics Stock Snapshot
Shares of Relmada Therapeutics, Inc. (NasdaqCM: RLMD) traded near $6.60. The company has a market cap of about $705.9 million. Its stock has seen a 52-week low of $0.52 and a high of $8.00. The 50-day moving average is $7.03, while the 200-day moving average is $4.61. Relmada boasts a strong current ratio of 80.21 and a quick ratio of 79.92, with a debt-to-equity ratio of just 0.095.
Insider Buying and Selling at Relmada Therapeutics, Inc.
In December 2025, Relmada's CEO, Dr. Sergio Traversa, and CFO, Maged Shenouda, each purchased 27,500 and 11,665 shares respectively at $4.12 per share. Additionally, COO Paul Edward Kelly acquired 828,000 shares on December 12, 2025. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 18, 2026, HC Wainwright & Co. reiterated its buy rating on Relmada Therapeutics with a $12 price target. Piper Sandler initiated coverage on March 24, 2026, also with a buy rating and a $12 target. Mizuho maintained its buy rating with a $19 target on March 20, 2026. The consensus among analysts is a buy rating, with an average price target of $12.80 based on five opinions.
About Relmada Therapeutics
Relmada Therapeutics, Inc. is a biotechnology company focused on developing treatments for central nervous system disorders. Based in Coral Gables, Florida, and led by CEO Dr. Sergio Traversa, the company is advancing several compounds through clinical trials, including NDV-01 and Sepranolone. Relmada employs 17 people and has partnerships with Asarina Pharma AB and Trigone.
Bottom Line
Relmada Therapeutics is drawing attention from analysts and investors alike, with HC Wainwright reiterating its buy rating and setting a $12 price target. While the company's stock is currently trading around $6.60, its innovative pipeline and institutional interest make it a company to watch. Remember, 13F filings and analyst ratings are backward-looking, reflecting past actions and opinions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.